Compare Merck & Co., Inc. (MRK) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Realty Income Corp — how do they compare? Merck & Co., Inc. trades at $146.2 (market cap $351.28B), while Realty Income Corp trades at $54.23 (market cap $51.26B). The key difference: Merck & Co., Inc. is far larger — about 6.9× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Realty Income Corp for 127 Days on average.
| MRK | O | |
|---|---|---|
Market Cap | $351.28B | $51.26B |
Volume | 7,969,665 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $156.43 | $67.56 |
52-Week Low | $82.49 | $53.35 |
Typical Hold Time | 98 Days | 127 Days |
Enterprise Value | $398.04B | $81.88B |
Dividend Yield | 2.39% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Realty Income (O) trades at $54.18, up 1.56% today, but remains in a bearish technical trend with recent earnings misses and a high P/E of 39.54. Revenue grew to $5.75B in 2025, with a net income margin of 21.23%, but rising debt levels and negative cash flow projections for 2026 pose concerns. Analyst sentiment is mixed, with a consensus price target of $64.80, though technical indicators signal caution.
The stock offers a defensive dividend play with consistent payouts, but faces headwinds from rising interest rates and elevated valuation. Upside depends on earnings recovery and debt management, while risks include further technical weakness and macroeconomic pressure on REITs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
